Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use ...
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...